RE: RE: Just a thought...Technicalbuy.. Thank you TechnicalBuy:
That is a most informative post. I had just completed a post on BTI after doing some reading on it and then read yours. I am hesitant to post it for fear of seeming negative. Also, after reading your post and information there are a few things which I am curious about...and some that I may be misinformed on. But to be fair, maybe I will just post it now because then your and others will be able to address it for the benefit of all, including myself.
I interpret what you say as meaning that 'Transcend" is not a drug per se but merely a delivery mechanism. A rudimentary comparison may be the cellulose capsule of a pill or the slow release drug mechanism of some pills...that basically get the drug into the gut before being released. I realize 'Transcend' is much more complex than that so I have assumed that it has pharmacological properties that are inert? So, it is not a 'drug' per se but a vehicle somehow bound with the drug? What would be most important to know is whether 'Transcend' has to pass all the initial regulatory hurdles of the multiple human clinical trial phases that all drugs must endure to discover therapeutic efficacy and also the feared potential for any side effects. The way I have understood you is that it does not because the drugs it will carry are already marketed successful, approved by the FDA...or are going through various clinical trial stages at this time by the major pharmaceutical houses.
I sold medical products and pharmaceuticals for 30 years and I was always annoyed with Doctors who wanted so much empirical evidence, even when the drug or therapy in question had been successfully practiced elsewhere. Now, after all that time I can appreciate why they were all from 'Missouri'. Here is my post with all of its warts. Believe me, I want this to be a big success because the patient/health care benefits will be astronomical. Hers is my initial post:
"I just did a little sourcing of information on BTI.
I’m sure you have all read the news releases of the last few years and no doubt know all this. Here is my take for what it may be worth, having spent 30 years in the medical and pharmaceutical business…and a sometimes investor.
The research to date has taken several years and progressed very well. This is a short time for this type of research. The technology is incredibly exciting and looks extremely promising at this advanced research stage. What looks like a breakthrough in transporting known drugs/therapeutics across the blood brain barrier has been made…so that they can be immensely more effective in targeting areas of focus for both diagnosis and treatment…such as cancer that has spread from breast tissue to the brain that can be attacked directly in the brain with Genentech’s drug Herceptin, which is carried to the site by Bioasis’s ‘Transcend’ vehicle or ‘carrier’.
The NRC study released in Aug/11 involved the intravenous administration of the drug/carrier combo in lab mice. This was a step forward from other tests done earlier at the NRC and BC cancer research center whereby tests done ‘in vitro’ (in the lab...not on humans) showed ‘promise’ for both cancer killing and delivery to brain cells.
A follow up study released in Oct. confirmed the earlier study on lab animals, showing a ‘markedly increased ability’ to kill the cancer cells that had spread from the breast to the brain. This study further supported the presence of the drug by way of imaging technology.
The Nov./11 release on another NRC set of test results showed successful delivery of an antibody (protein), an ‘anti-amyloid (an amyloid is a waxy glycoprotein)’, into the brain. The belief is that these waxy particles are thought to be responsible for Alzheimer’s Disease and that an attack on these plaque forming particles can now be achieved by successful delivery of the antibody across the brain barrier. There are many pharmaceutical companies in various stages of clinical trials developing these plaque attacking anti bodies.
The Nov. 24th NR announced a research and evaluation agreement with Shire. More promising news. Shire may been given the option to obtain a license from biOasis to use ‘Transcend’ under mutually agreed to terms. Shire’s objective is to find a way to deliver special enzymes to the brain that can treat certain metabolic disorders.
BTI’s ‘Transcend’ delivery technology looks very promising and one can understand the ramifications should other major pharmaceutical researchers and companies wish to do research studies and if successful, eventually license the product. It would appear that huge cash flow for BTI is possible with so many drugs and future drugs could be most effective for so many treatments.
Many acknowledged and respected medical researchers and others have been added to the team over the last few years that have no doubt shortened BTI’s take off towards human clinical trials. To date only a few trials have been successfully completed with mice or other lab animals…or in ‘test tube’ experiments. This is not to demean the progress that has been made because that in itself is remarkable and holds unbelievable promise…most especially when considering only one disease, that of Alzheimer’s, which by itself would have global impact…and be worth billions and billions.
While all the above is impulsively promising and unimaginably exciting, there is still a long way to go through the maze of necessary FDA regulations and multiple staged, massive, in-depth trials on humans.?
So, where does that leave me? I have invested in medical stocks many times over the years and have not had any success…from intense light treatment of injected cancer drugs to potential memory drugs. The first one I remember was one that Abbott Labs spent over $7 million (about $100 million today)on by 1966…called Cylert. It worked great on rats but not on humans. It was a bust…and there are thousands of such examples. Please do not think I am saying that BTI is in any way similar to the above or tainted by all that. We need what they have to offer most desperately.
Another factor that has to be seriously considered today is the potential for harmful side effects. Ever watch a TV commercial on a drug lately? This is one of the most pressing obstacles in the way of new drugs coming to market…and it takes a long time to understand exactly what the unknowns are. It is not even fair is many respects because legitimate life saving drugs may be erroneously held off the market for years.
So, while I think the stock is not priced badly here, a lot has to do with premature expectation because of the mind blowing potential, excitement and promise. It may very well go much higher, hope it does. But, I will wait until the real trials start on real patients. If BTI has what it appears to have, it will be worth billions. I can only hope and prey that BTI is what it appears to be. Cancer and Alzheimer’s has touched us all.
So, we will have to wait some time before the verdicts come in. Patience is a virtue.
Good luck all …most especially to the good folks at BTI...and I anxiously await continuing news from BTI.